Journal of the National Comprehensive Cancer Network : JNCCN

, volume 19 , issue 13 , pages 11-17

Telemedicine in Oncology and Reimbursement Policy During COVID-19 and Beyond

Sheetal M. Kircher ^{1, 2}

Mary Mulcahy ^{1, 2}

Aparna Kalyan ^{1, 2}

Christine B Weldon ^{2, 3}

Julia R Trosman ^{2, 3}

Al B. Benson ^{1, 2}

Hide authors affiliations Show authors affiliations: 3 affiliations

1Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago; |

2Northwestern University, Feinberg School of Medicine, Chicago; and |

3Center for Business Models in Healthcare, Glencoe, Illinois. |

Publication type: Journal Article

Publication date: 2021-03-01

Harborside Press, LLC

Journal of the National Comprehensive Cancer Network : JNCCN

scimago Q1

wos Q1

SJR: 5.514

CiteScore: 24.7

Impact factor: 16.4

ISSN: 15401405, 15401413

DOI: 10.6004/jnccn.2020.7639

Copy DOI

PubMed ID: 32998106

Oncology

Abstract

The first confirmed case of coronavirus disease 2019 (COVID-19) in the United States was reported on January 20, 2020. As of September 17, 2020, there were more than 6.6 million confirmed cases and 196,277 deaths. Limited data are available on outcomes of immunocompromised patients, but early published reports from China indicate that those with cancer have a 3.5 times higher risk of ICU admission, mechanical ventilation, or death than those without cancer. Because of the uncertain behavior of COVID-19, it has become imperative for practices to limit exposure to vulnerable patients. Telemedicine has been one of the cornerstones of caring for patients with cancer during the COVID-19 pandemic. This review provides an overview of reimbursement policy by public and private payers before and during the COVID-19 pandemic, describes implications in cancer care, and offers considerations for future reimbursement policy.

Found

Top-30

Journals

Publishers

	1 2 3 4 5 6 7
JMIR Publications	JMIR Publications, 7, 41.18% JMIR Publications 7 publications, 41.18%
Springer Nature	Springer Nature, 4, 23.53% Springer Nature 4 publications, 23.53%
Ovid Technologies (Wolters Kluwer Health)	Ovid Technologies (Wolters Kluwer Health), 1, 5.88% Ovid Technologies (Wolters Kluwer Health) 1 publication, 5.88%
Oxford University Press	Oxford University Press, 1, 5.88% Oxford University Press 1 publication, 5.88%
American Society of Health-System Pharmacists	American Society of Health-System Pharmacists, 1, 5.88% American Society of Health-System Pharmacists 1 publication, 5.88%
Mary Ann Liebert	Mary Ann Liebert, 1, 5.88% Mary Ann Liebert 1 publication, 5.88%
Institute of Electrical and Electronics Engineers (IEEE)	Institute of Electrical and Electronics Engineers (IEEE), 1, 5.88% Institute of Electrical and Electronics Engineers (IEEE) 1 publication, 5.88%
American Medical Association (AMA)	American Medical Association (AMA), 1, 5.88% American Medical Association (AMA) 1 publication, 5.88%
	1 2 3 4 5 6 7

We do not take into account publications without a DOI.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

Metrics

Cite this

GOST |

Cite this

GOST Copy

Kircher S. M. et al. Telemedicine in Oncology and Reimbursement Policy During COVID-19 and Beyond // Journal of the National Comprehensive Cancer Network : JNCCN. 2021. Vol. 19. No. 13. pp. 11-17.

GOST all authors (up to 50) Copy

Kircher S. M., Mulcahy M., Kalyan A., Weldon C. B., Trosman J. R., Benson A. B. Telemedicine in Oncology and Reimbursement Policy During COVID-19 and Beyond // Journal of the National Comprehensive Cancer Network : JNCCN. 2021. Vol. 19. No. 13. pp. 11-17.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.6004/jnccn.2020.7639

UR - https://jnccn.org/view/journals/jnccn/19/13/article-p11.xml

TI - Telemedicine in Oncology and Reimbursement Policy During COVID-19 and Beyond

T2 - Journal of the National Comprehensive Cancer Network : JNCCN

AU - Kircher, Sheetal M.

AU - Mulcahy, Mary

AU - Kalyan, Aparna

AU - Weldon, Christine B

AU - Trosman, Julia R

AU - Benson, Al B.

PY - 2021

DA - 2021/03/01

PB - Harborside Press, LLC

SP - 11-17

IS - 13

VL - 19

PMID - 32998106

SN - 1540-1405

SN - 1540-1413

ER -

BibTex |

Cite this

BibTex (up to 50 authors) Copy

@article{2021_Kircher,

author = {Sheetal M. Kircher and Mary Mulcahy and Aparna Kalyan and Christine B Weldon and Julia R Trosman and Al B. Benson},

title = {Telemedicine in Oncology and Reimbursement Policy During COVID-19 and Beyond},

journal = {Journal of the National Comprehensive Cancer Network : JNCCN},

year = {2021},

volume = {19},

publisher = {Harborside Press, LLC},

month = {mar},

url = {https://jnccn.org/view/journals/jnccn/19/13/article-p11.xml},

number = {13},

pages = {11--17},

doi = {10.6004/jnccn.2020.7639}

}

MLA

Cite this

MLA Copy

Kircher, Sheetal M., et al. “Telemedicine in Oncology and Reimbursement Policy During COVID-19 and Beyond.” Journal of the National Comprehensive Cancer Network : JNCCN, vol. 19, no. 13, Mar. 2021, pp. 11-17. https://jnccn.org/view/journals/jnccn/19/13/article-p11.xml.

Publisher

Harborside Press, LLC

Journal

Journal of the National Comprehensive Cancer Network : JNCCN

scimago Q1

wos Q1

SJR

5.514

CiteScore

24.7

Impact factor

16.4

ISSN

15401405 (Print)

15401413 (Electronic)